DermBiont’s mission is to become the world’s leading precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root cause of skin diseases with biotherapeutics that repair an imbalance of the microbiome as well as through the development of targeted small molecule therapeutics with well-defined mechanisms of action. DermBiont’s biotherapeutics discovery team leverages computational biology and a proprietary bioinformatics platform to identify clinically meaningful dysbiosis related to common skin diseases and mines a curated library of microbes to build a pipeline of products to treat identified dysbiosis across indications.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $71.2M
Founded date: 2017
Investors 6
| Date | Name | Website |
| - | Civilizati... | civilizati... |
| - | Joyance Pa... | joyancepar... |
| - | Start Capi... | start-capi... |
| - | Olive Tree... | olivetreec... |
| - | SymBiosis | symbiosis.... |
| - | Alchimia I... | alchimiain... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.10.2023 | Series B | $35.2M | - |
| 21.12.2021 | - | $28M | - |
| 18.06.2019 | Series A | $8M | - |
Mentions in press and media 14
| Date | Title | Description |
| 24.10.2023 | DermBiont Closes $35.2M in Series B Funding | DermBiont, a Boston, MA-based clinical-stage biotechnology company, raised $35.2M in Series B funding, including a $27.1M Series B first close and $8.1M in converting outstanding notes. The round was led by Double Point Ventures with partic... |
| 02.10.2022 | The Motivation Behind our Microbiome Focus | Photo by CDC on Unsplash Scientific exploration of the microbiome represents the opening of one of the greatest areas of science in decades, perhaps centuries. The biome utterly defines novel new approaches to the prevention and treatment ... |
| 07.01.2022 | StartUPDATES: New developments from healthcare startups | DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, recently announced the completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 mill... |
| 24.12.2021 | StartUPDATES: New developments for healthcare startups | DermBiont, a clinical stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, has raised a $28 million Series A2 financing. It has also acquired clinical-stage biotechnology compan... |
| 21.12.2021 | DermBiont Raises $28 Million in Series A2 Funding; Acquires Chromaderm | DermBiont, a Boston, MA-based clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, raised $28m in Series A2 financing. Backers included Pivotal Life Sciences (lead), Vi... |
| 08.01.2021 | DermBiont Announces Positive Results in Phase 2a Clinical Trial in Atopic Dermatitis with a Topical Live Biotherapeutic | “We learn more about the microbiome and how to make live bacterium into drug products with each clinical trial that we run at DermBiont,” said Dr. Robert Brucker, a co-founder and CSO. BOSTON (PRWEB) January 08, 2021 DermBiont, a clinical-s... |
| 08.01.2021 | DermBiont Announces Positive Results from Phase 2b Clinical Trial in Tinea Pedis | “DermBiont was founded to lead the field of evidence-based dermatology therapeutics that treat diseases at their root cause,” said Nichola Eliovits, a co-founder and CBO. BOSTON (PRWEB) January 08, 2021 DermBiont, a clinical-stage biotechno... |
| 01.10.2020 | Trusting Your Gut: How Our Portfolio Companies are Taking Advantage of the Microbial Revolution | Last month marked an important step for microbiome science: Cambridge, MA-based biotechnology company Seres Therapeutics reported positive results from their Phase III human clinical trial of an oral microbiome therapeutic for the treatment... |
| 18.06.2019 | DermBiont Raises $8M in Series A Funding | DermBiont, a Boston, MA-based clinical stage therapeutics company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases, closed an $8M Series A funding. The round was led by Zola Global Inv... |
| 02.05.2019 | Press Release: Joyance Partners Announces European Expansion | London, UK - May 02, 2019 -- Joyance Partners, a venture capital partnership that invests in early-stage companies that deliver delightful moments, announced today its expansion into Europe and the addition of three new team members. "... |
Show more